Gili Hart
Net worth: 6 214 $ as of 31/05/2026
Net worth: 6 214 $ as of 31/05/2026
Gili Hart currently works at SpliSense Ltd., as Chief Executive Officer from 2020, Quicklizard Ltd., as Independent Director from 2021, and Enlivex Therapeutics Ltd., as Independent Director from 2014.
Dr. Hart also formerly worked at OPKO Biologics Ltd., as Chief Executive Officer from 2004 to 2017, Mitoconix Bio Ltd., as Chief Executive Officer from 2017 to 2020, Enlivex Therapeutics Ltd., as Director, CollPlant Biotechnologies Ltd., as Independent Director from 2021 to 2023, OPKO Health, Inc., as Vice President-Biologics, and Prolor Biotech Ltd., as VP-Pre-Clinical & Clinical Pharmacology from 2009 to 2013.
Dr. Hart received her graduate degree and doctorate degree from Weizmann Institute of Science and undergraduate degree from Technion Institute.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 18/03/2026 | 7,672 ( 0% ) | 6 214 $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| ENLIVEX LTD. | Director/Board Member | 01/01/2014 |
| QUICKLIZARD LTD | Director/Board Member | 21/02/2021 |
SpliSense Ltd.
SpliSense Ltd. Pharmaceuticals: MajorHealth Technology Develops antisense therapeutics for genetic diseases | Chief Executive Officer | 01/01/2020 |
| Companies | Position | End |
|---|---|---|
| COLLPLANT BIOTECHNOLOGIES LTD. | Director/Board Member | 05/07/2023 |
Mitoconix Bio Ltd.
Mitoconix Bio Ltd. BiotechnologyHealth Technology Develops novel therapeutics to improve mitochondrial health as a disease-modifying therapeutics for neurodegenerative diseases | Chief Executive Officer | 01/01/2020 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. BiotechnologyHealth Technology Operates as a drug development company that develops bio-better long-acting therapeutic proteins | Chief Executive Officer | 01/01/2017 |
Prolor Biotech Ltd.
Prolor Biotech Ltd. BiotechnologyHealth Technology Develops proprietary versions of already-approved therapeutic proteins | Corporate Officer/Principal | 01/01/2013 |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Director/Board Member | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 11 |
|---|---|
OPKO Biologics Ltd.
OPKO Biologics Ltd. BiotechnologyHealth Technology Operates as a drug development company that develops bio-better long-acting therapeutic proteins | Health Technology |
Weizmann Institute of Science
Weizmann Institute of Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OPKO Health, Inc.
OPKO Health, Inc. Medical/Nursing ServicesHealth Services Engages in biopharmaceutical and diagnostics | Health Services |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Health Technology |
CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd. Medical SpecialtiesHealth Technology Develops and commercializes medical devices | Health Technology |
Technion Institute
Technion Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Quicklizard Ltd.
Quicklizard Ltd. Packaged SoftwareTechnology Services Develops AI based pricing platform for e-Commerce and Omni channel retailers | Technology Services |
Prolor Biotech Ltd.
Prolor Biotech Ltd. BiotechnologyHealth Technology Develops proprietary versions of already-approved therapeutic proteins | Health Technology |
Mitoconix Bio Ltd.
Mitoconix Bio Ltd. BiotechnologyHealth Technology Develops novel therapeutics to improve mitochondrial health as a disease-modifying therapeutics for neurodegenerative diseases | Health Technology |
Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd. BiotechnologyHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Health Technology |
SpliSense Ltd.
SpliSense Ltd. Pharmaceuticals: MajorHealth Technology Develops antisense therapeutics for genetic diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions